Spectral Molecular Imaging, Inc. Announces Accelerated Timeline for its Early Melanoma Detection Product SkinSpect(TM)

Published: Aug 26, 2010

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Cascade Technologies, Inc. (OTCBB: CSDT) announced today that its wholly-owned subsidiary Spectral Molecular Imaging, Inc. (SMI) will complete development of its new product SkinSpectâ„¢, aimed at early detection of melanoma by hyperspectral imaging, in mid-September 2010, significantly ahead of schedule. The device incorporates new advances in component technologies (optics, cameras, displays, embedded computers and software), as well as experience derived from previous prototypes developed under federal funding and tested in the clinic. The spectral range covered is also extended, now ranging from 385 nm to 920 nm.

Back to news